All the Active Ingredient Drugs
Monoclonal Antibody. Daratumumab 20 mg/ml. Vial. Conc. for sol. for inf. 1 X 5ml or 20 ml
Recomm dose: 16 mg/kg BW as IV inf. See full prescription info.
In comb. with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the tmt of adlts with newly diagn. multiple myeloma (MM) who are ineligible for autologous stem cell transplant.
* In comb. with bortezomib, thalidomide and dexamethasone for the tmt of adlts with newly diagn. MM who are eligible for autologous stem cell transplant.
* In comb. with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for adlts with MM who have received at least one prior ther.
* Monother. for adults with relapsed and refractory MM whose prior ther. included a proteasome inhib. and an immunomodulatory agent and who have demonstr. dis. progress. on the last ther.
C/I:Hypersens.
Monoclonal Antibody. Daratumumab 120 mg/ml. Vial Sol. for inj. 1 X 15 ml
Recomm. dose is 1800 mg as SC inject. . See full prescript. info
Multiple myeloma (MM)
* In comb. with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for adults with newly diagn. MM who are ineligible for autologous stem cell transplant.
* In comb. with bortezomib, thalidomide and dexamethasone for adults with newly diagn. MM who are eligible for autologous stem cell transplant.
* In comb. with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for adults with MM who have received at least one prior ther.
* in comb. with pomalidomide and dexamethasone, for adults with MM who have received at least one prior line of ther. incl. lenalidomide and a proteasome inhib.
* As monother. for adults with relapsed and refractory MM, whose prior ther. incl. a proteasome inhib. and an immunomodulatory agent and who have demonstr. dis. progress. on the last ther.
* In comb. with bortezomib, lenalidomide and dexamethasone for adults with newly diagn. MM who are ineligible for autologous stem cell transplant.
* In comb. with bortezomib, lenalidomide, and dexamethasone, followed by maint. tmt. in comb. with lenalidomide, for adults with newly diagn. MM who are eligible for autologous stem cell transplant.
Light chain (AL) amyloidosis
In comb. with cyclophosphamide, bortezomib and dexamethasone for adults with newly diagn. syst. AL amyloidosis.
C/I: Hypersens.
